NCT05665374Completed
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
General Use-Results Study of Calquence Capsules 100 mg in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 67 (actual)
- First submitted
- 16 Dec 2022
- Start date
- Jun 2023
- Primary completion date
- Aug 2025
- Lead sponsor
- AstraZeneca
- NCT number
- NCT05665374
What you commit to
- Study type: Observational
- Participants enrolled: 67
- From Jun 2023 to the primary completion date, Aug 2025
- 15 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
- \-
Who the study is looking for
- Patients with previously untreated chronic lymphocytic leukaemia (including small lymphocytic lymphoma) who are treated with Calquence for the first time will be enrolled in the study after the approval date of the sJNDA for the additional indication.
- \-
Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.